ArticleSleep science (Sao Paulo, Brazil)2026
Acute Onset of Suicidal Ideation after Starting Lemborexant in a Patient with a Mood Disorder.
Article in Sleep science (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 24-year-old woman with treatment-resistant depressive symptoms and chronic insomnia developed acute, intrusive suicidal ideation with intent on day 5 after starting lemborexant 10 mg nightly. Emergency assessment did not identify intoxication, metabolic disturbance, psychosis, mania, akathisia, or other acute precipitants. Pretreatment polysomnography showed severe insomnia with a sleep efficiency of 14.5% and absent REM sleep, without sleep-disordered breathing. Lemborexant was discontinued immediately, and suicidal ideation resolved completely within 24 hours without additional pharmacological intervention. The Naranjo Adverse Drug Reaction Probability Scale yielded a score of 6, consistent with a probable adverse drug reaction. At 6-month follow-up, the patient remained free of suicidal ideation with sustained functional stability. This case adds clinically relevant documentation to pharmacovigilance concerns about potential suicidality with dual orexin receptor antagonists and supports structured suicide risk assessment and early follow-up when initiating these agents in patients with mood disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.